Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to address unmet medical needs [3] - The company's lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell therapy derived from the bone marrow of young, healthy adult donors [3] - Lomecel-B™ has multiple potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair effects, with applications across various disease areas [3] Pipeline and FDA Designations - Longeveron is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and aging-related frailty [3] - The HLHS program has received three important FDA designations: Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation [3] - The Alzheimer's disease program has received two significant FDA designations: Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation [3] Upcoming Financial Results - Longeveron will report its full-year 2024 financial results and provide a business update on February 28, 2025, after U.S. financial markets close [1] - A conference call and webcast will be held on the same day at 4:30 p.m. ET [1][2]

Cellular therapy Lomecel-B™ has been granted an International Non-proprietary Name (INN) of "laromestrocel" on the INN List issued by the World Health Organization (WHO)Lomecel-B™ is a proprietary, scalable, allogeneic cellular therapy being evaluated in Alzheimer's disease and hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan indicationLomecel-B™ first cellular therapeutic candidate to receive U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Alzheimer's disea ...

Wa'el Hashad Wa'el Hashad, CEO, Longeveron Cellular therapy Lomecel-B™ has been granted an International Non-proprietary Name (INN) of “laromestrocel” on the INN List issued by the World Health Organization (WHO)Lomecel-B™ is a proprietary, scalable, allogeneic cellular therapy being evaluated in Alzheimer’s disease and hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan indicationLomecel-B™ first cellular therapeutic candidate to receive U.S. FDA Regenerative Medicine Advanced T ...

Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to address unmet medical needs [3] - The company's lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell therapy derived from the bone marrow of young, healthy adult donors [3] - Lomecel-B™ has multiple potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair effects, with applications across various disease areas [3] Pipeline and FDA Designations - Longeveron is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and aging-related frailty [3] - The HLHS program has received three important FDA designations: Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation [3] - The Alzheimer's disease program has received two FDA designations: Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation [3] Upcoming Events - Longeveron will participate in the Emerging Growth Virtual Conference on February 18-19, 2025, with a presentation scheduled for February 19, 2025, from 3:10 to 3:20 p.m. ET [1] - The webcast for the conference presentation will be accessible on the company's website, with a replay available for 180 days post-conference [1]

MIAMI, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa'el Hashad, Chief Executive Officer, will give a corporate presentation at Biotech Showcase, being held January 13-15, 2025. Details for the Company's presentation: Date:Tuesday, January 14, 2025Time:4:00 – 4:30 p.m. PT   The webcast for this conference presentation ...

MIAMI, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the Emerging Growth Virtual Conference taking place December 4-5, 2024. Details for the Company’s presentation: Date:December 5, 2024Time:12:00 – 12:30 p.m. ET   The webcast for this conference presentation may be accessed at the “Events and Pre ...

Longeveron, Inc. (NASDAQ:LGVN) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - CMO Lisa Locklear - CFO Joshua Hare - Co-Founder, Chief Science Officer & Chairman Conference Call Participants Boobalan Pachaiyappan - ROTH Capital Partners Operator Ladies and gentlemen, greetings and welcome to the Longeveron Third Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. A ...

Exhibit 99.1 LongeveronAnnounces Third Quarter 2024 Financial Results and Provides Business Update ● Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B in rare pediatric disease HLHS has achieved more than 80% enrollment ● Positive Type C meeting with U.S. FDA confirmed ELPIS II is pivotal and, if positive, acceptable for Biological License Application (BLA) submission for full traditional approval ● Positive data from the Phase 2a clinical trial (CLEAR MIND) evaluating Lomecel-B in Alzheimer's disease ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40060 Longeveron Inc. (Exact name of registrant as specified in its charter) Delaware 47-2174146 (State or Other Jurisdiction of Inc ...

Findings offer potential mechanistic and clinical insights in the development of cellular therapy LomecelB™ for mild Alzheimer's disease (AD) Lomecel-B™ capacity to inhibit MMP14 correlates with improved clinical and biomarker outcomes in mild AD Immunomodulatory and pro-vascular effects of Lomecel-B™ in mild AD potentially driven by ability to exert MMP14 inhibition which may protect TIE2 receptor integrity in human AD patients MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clin ...